An Airline, Biotechs, and More See Huge Insider Buying
Public offerings of stock and activist investor activity prompted some huge insider buying at an entertainment company, an airline, biotechs, and more.
Headquartered in Norwood, MA Fiscal year ends December NASDAQ: CRBP corbuspharma.com
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company developing new therapies in oncology and obesity. It has no commercial products or revenue.
Its lead oncology asset is sutantatug envedotin (CRB-701), a next-generation Nectin-4-targeting antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical. It is being developed for oropharyngeal squamous cell carcinoma (a subtype of head and neck cancer) and cervical cancer, and holds FDA Fast Track designations in both. The drug is in the registrational TEMPO-1 study in second-line-plus OPSCC, and combination data with Keytruda in the first-line setting are expected in Q1 2027.
In obesity, Corbus is developing CRB-913, an oral, peripherally restricted CB1 inverse agonist positioned as a potential non-incretin oral weight-loss medicine. CRB-913 has completed the CANYON-1 Phase 1b study.
The company funds operations from its cash and investments and owes milestone payments under its CSPC license. Updated
Public offerings of stock and activist investor activity prompted some huge insider buying at an entertainment company, an airline, biotechs, and more.
A public offering of shares this past week prompted a huge purchase from a beneficial owner. Meanwhile, a couple of repeat buyers further boosted their stakes as well.
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA | NVDA Price Prediction) to the forefront of the industry.…
Warren Buffett boosts his stake in this tracking stock again, plus notable insider buying of communication and aviation stocks in the past week.
Another huge Warren Buffett purchase highlighted the past week's insider buying, and a couple of IPOs also prompted insiders to action.
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Robinhood has become the dominant discount brokerage platform over the last year. It had 4.3 million average revenue trades in June, which is a critical metric in the industry. This is higher…
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company developing new therapies in oncology and obesity. It has no commercial products or revenue.
The Wall Street consensus 12-month price target for CRBP is $33.22.